Increased incidence of hepatocellular and intrahepatic cholangiocellular cancer in the Northeast of Germany;Zunahme des hepatozellulären und des intrahepatischen cholangiozellulären karzinoms im Nordosten Deutschlands

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 30, 2006, Pages 1649-1655

  Schurr, R ^a   Stolzel U ^b   Schuppan, D ^c   Schwertner, C ^d   Steinberg, J ^d   Scherubl H ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VIVANTES KLINIKUM AM URBAN   (Germany)

Author keywords

Biliary neoplasm; Liver carcinoma; Tumor registry

Indexed keywords

ARTICLE; BILE DUCT CANCER; CANCER REGISTRY; GERMANY; HUMAN; INCIDENCE; INTRAHEPATIC CHOLANGIOCELLULAR CANCER; LIVER CELL CARCINOMA; PROGNOSIS; ADULT; AGE DISTRIBUTION; AGED; BILE DUCT CARCINOMA; BILE DUCT TUMOR; FEMALE; INTRAHEPATIC BILE DUCT; LIVER TUMOR; MALE; MIDDLE AGED; REGISTER; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; GERMANY; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; REGISTRIES; SEX DISTRIBUTION;

EID: 33747170618     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947811     Document Type: Article

References (42)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16
2. Blum HE, Spangenberg HC, Zuber-Jerger I, Mohr L, Thimme R. Diagnostik und Therapie des hepatozellulären Karzinoms. Dtsch Med Wochenschr 2004; 129: 368-372
3. Caldwell SH, Crespo DM, Kong HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-103
4. Caselmann WH, Blum HE et al. Leitlinien der Deutschen Gesellschaft fur Verdauungs- und Stoffwechselkrankheiten zur Diagnostik und Therapie des hepatozellularen Karzinoms. Z Gastroenterol 1999; 37: 353-365
5. Chang MH, Chen CJ, Lai MS et al. Taiwan Childhood Hepatoma Study Group. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 1855-1859
6. Chen C, Yang H et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73
7. Colombo M, Kuo G, Choo QL et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; 2: 1006-1008
8. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27: 914-919
9. Donato F, Tagger A, Gelatti U et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-331
10. Deuffic S, Buffat L, Poynard T, Volleren AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-1601
11. Deuffic S, Poynard T, Valleron AJ. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat 1999; 6: 411-413
12. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
13. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468
14. Erhardt A, Theobald I, Petry W et al. Hepatozelluläres Karzinom: Steigende Inzidenz der Hepatitis-C-bedingten Fälle einer Universitätsklinik in Deutschland. Dtsch Med Wochenschr 2002; 127: 2665-2668
15. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97: 2886-2895
16. Fattovich G, Stroffolini T et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50
17. Fleig WE. Hepatozellulares Karzinom: Lokoregionäre Therapie. Dtsch Med Wochenschr 2003(Suppl 2128: S102-310
18. Gürtler L. Hepatitis C in Deutschland. Über 5000 Neuinfektionen jährlich. MMW Fortschr Med 2002; 144: 26-28
19. Herold C, Ganslmayer M, Ocker M et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233-240
20. Höpfner M, Huether A, Sutter A, Baradari V, Schuppan D, Scherübl H. Blockade of the IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular cancer cells. Biochem Pharm 2006; 71: 1435-1448
21. Huether A, Hopfner M, Sutter AP, Schuppan D, Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005; 43: 661-669
22. Island ER, Pomposelli J, Pomfret EA, Gordon FD, Lewis WD, Jenkins RL. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 2005; 140: 353-358
23. Kaczynski J, Oden A. The rising incidence of hepatocellular carcinoma. N Engl J Med 1999; 341: 451
24. Khurana V, Saluja A, Caldito G, Fort C, Schiff ER. Statins are protective against hepatocellular cancer in patients with hepatitis C virus infection: Half a million Us veterans' study. Abstract S1535. DDW Chicago, IL, 2005
25. Kubicka S, Rudolph KL, Hanke M et al. Hepatocellular carcinoma in Germany: a retrospective epidemiological study from a low-endemic area. Liver 2000; 20: 312-318
26. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-71
27. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003(Suppl 138: S136-149
28. McGlynn KA, Tsao L, Hsing AW et al. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-296
29. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626
30. Simonetti RG, Comma C, Fiorello F, Politi F, D'Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis SCi 1991; 36: 962-972
31. Stroffolini T. Etiological factor of hepatocellular carcinoma in Italy. Minerva Gastroenterol Dietol 2005; 51: 1-5
32. Strumberg D, Richly H, Hilger RA et aL. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972
33. SuTTer AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43: 808-816
34. Taylor-Robinson SD, Foster GR, Arora S et al. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143
35. Trevisani F, Cantarini MC, Labate AM et al. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol 2004; 99: 1470-1476
36. Tsukuma H, Hiyama T et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-1801
37. Verhoef C, Visser O, de Man RA, de Wilt JH, Jzermans J, Janssen-Heijnen ML. Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns. Eur J Cancer 2004; 40: 1530-1538
38. Vong S, Bell BP. Chronic liver disease mortality in the United States, 1990-1998. Hepatology 2004; 39: 476-483
39. Wiegand J, Kaiser T, Lobstein S et al. Low prevalence of chronic hepatitis C, but high prevalence of elevated aminotransferases in a cohort of 2026 patients referred for orthopaedic surgery in the eastern part of Germany. Z Gastroenterol 2006; 44: 11-14
40. Yang B, Zhang B, Xu Y et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357-360
41. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127: S72-78
42. Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005; 70: 1568-1578